Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
K+S Raises 2026 Earnings Outlook After Strong Q1 Results 
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Orion Group purchased a controlling stake in LegoChem Biosciences, a South Korean research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines. The confectionery company is acquiring a 25.7% stake worth KRW550 billion or around $418 million.
With the size of its acquisition, the Orion Group has now become the largest shareholder of LegoChem Biosciences. The firm made the deal as it seeks to broaden its business and enter into new drug development business beyond antibody-drug conjugate platform technology, as per the Korea Joongang Daily.
What is Included in the Agreement
Pan Orion Corporation, the Hong Kong-headquartered subsidiary of the Orion Group, led the acquisition deal. Based on the reports, the agreement includes a combination of share purchases and rights offerings.
Moreover, it was stated in the electronic disclosure of the Financial Supervisory Service that Orion will buy 7.96 million units of new stakes at KRW59,000 per share. In addition, it will also purchase 1.4 million existing shares at the base rate of 56,186 per share. Orion is scheduled to settle the payment for the acquisition on March 29.
Orion's Venture Into Biotech Business
The Korea Economic Daily reported that this buyout deal not only marks the Orion Group's deeper venture into the biotech industry but is also expected to help the company in achieving its goal of giving a boost to LegoChem Biosciences by providing the needed financial push for clinical development and encouraging new technology research.
Once the deal is completed, Orion will be the largest shareholder in LegoChem Biosciences. Currently, the company's chief executive officer, Kim Yong Zu, holds the biggest share, and after the acquisition, he will still retain some of his shares and keep his CEO position. LegoChem is also set to become one of the confectionery giant's affiliates.
Photo by: Orion Website
